梅花生物：公司暂未进行股份回购

Group 1 - The company, Meihua Biological, announced on February 4 that as of the end of January 2026, it has not yet conducted any share buybacks and will implement the buyback plan based on market conditions in the future [1] Group 2 - The article discusses Kevin Warsh's new policy ideas, which suggest a dual approach of monetary easing and tightening, utilizing AI to manage inflation while rejecting the role of a major buyer of U.S. Treasury bonds [1]